2/22/2010

The FDA plans to ask a panel of experts to conduct a safety review of GlaxoSmithKline's Avandia in response to complaints from Sens. Max Baucus, D-Mont., and Chuck Grassley, R-Iowa, about the risk of heart attack associated with the diabetes drug, sources said. FDA Commissioner Margaret Hamburg will gather "FDA scientists and outside experts to gain a full understanding and awareness of all of the data and issues involved," an agency spokeswoman said.

Related Summaries